Table 4.
Mean and standard deviation (SD) scores of ESAS-r scales for each severity group (mild or moderate/severe) and for each product group (CBD/CBD or CBD/THC:CBD)
| Mean (SD) | Pain | Anxiety | Depression | Wellbeing |
|---|---|---|---|---|
| Baseline (sample size) | 277 | 270 | 272 | 268 |
| Overall sample | 5.14 (2.57) | 3.86 (3.19) | 3.16 (3.08) | 5.34 (2.61) |
| Mild severity group | 1.69 (1.1) | 0.99 (1.15) | 0.87 (1.18) | 1.86 (1.18) |
| Moderate or severe severity group | 6.34 (1.7) | 6.61 (1.78) | 6.3 (1.86) | 6.47 (1.83) |
| CBD/CBD group | 5.03 (2.66) | 3.80 (3.21) | 2.99 (3.04) | 5.28 (2.72) |
| CBD/THC:CBD group | 5.28 (2.45) | 3.95 (3.17) | 3.40 (3.13) | 5.42 (2.46) |
| FUP1 (sample size) | 262 | 261 | 261 | 254 |
| Overall Sample | 4.37 (2.73) | 2.93 (2.95) | 2.33 (2.79) | 4.45 (2.6) |
| Mild severity group | 2.3 (2.4) | 1.62 (2.08) | 1.12 (1.78) | 3.73 (2.75) |
| Moderate or severe severity group | 5.04 (2.49) | 4.15 (3.09) | 3.77 (3.07) | 4.72 (2.5) |
| CBD/CBD group | 4.09 (2.67) | 2.74 (2.87) | 2.23 (2.71) | 4.43 (2.6) |
| CBD/THC:CBD group | 4.75 (2.78) | 3.2 (3.05) | 2.47 (2.9) | 4.49 (2.63) |
| FUP2 (sample size) | 101 | 99 | 102 | 97 |
| Overall Sample | 4.7 (2.7) | 2.85 (3.01) | 2.67 (3.02) | 4.57 (2.47) |
| Mild severity group | 2.18 (2.43) | 1.32 (1.89) | 1.52 (2.31) | 3.82 (2.81) |
| Moderate or severe severity group | 5.2 (2.47) | 3.96 (3.19) | 3.74 (3.26) | 4.93 (2.23) |
| CBD/CBD group | 4.55 (2.6) | 2.44 (2.68) | 2.44 (2.82) | 4.76 (2.22) |
| CBD/THC:CBD group | 4.88 (2.81) | 3.08 (3.07) | 2.94 (3.24) | 4.36 (2.73) |
The CBD/THC:CBD group is composed of patients who added THC to their CBD-rich prescription during FUP1. ESAS-r scores varied between 0 and 10 for all assessed symptoms and all visits except for the anxiety scale at FUP2 for which the maximum score was 9
CBD cannabidiol, FUP1 follow-up visit at 3 month, FUP2 follow-up visit at 6 month, THC Δ9-tetrahydrocannabinol